Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-4.46 Insider Own0.00% Shs Outstand3.65M Perf Week-4.05%
Market Cap6.83M Forward P/E- EPS next Y-4.50 Insider Trans- Shs Float3.65M Perf Month8.15%
Income-16.25M PEG- EPS next Q-1.04 Inst Own8.33% Short Float0.22% Perf Quarter-9.17%
Sales6.80M P/S1.00 EPS this Y20.51% Inst Trans-54.58% Short Ratio0.44 Perf Half Y-20.38%
Book/sh5.44 P/B0.34 EPS next Y-3.69% ROA-39.06% Short Interest0.01M Perf Year-44.32%
Cash/sh5.89 P/C0.32 EPS next 5Y- ROE-59.18% 52W Range1.64 - 3.50 Perf YTD0.59%
Dividend Est.- P/FCF- EPS past 5Y50.62% ROI-57.43% 52W High-46.54% Beta0.93
Dividend TTM- Quick Ratio5.24 Sales past 5Y1272.01% Gross Margin75.66% 52W Low14.09% ATR (14)0.11
Dividend Ex-Date- Current Ratio5.24 EPS Y/Y TTM32.16% Oper. Margin-247.50% RSI (14)50.02 Volatility4.86% 5.38%
Employees29 Debt/Eq0.43 Sales Y/Y TTM41.19% Profit Margin-238.89% Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.42 EPS Q/Q28.86% Payout- Rel Volume0.26 Prev Close1.91
Sales Surprise-5.85% EPS Surprise1.90% Sales Q/Q-6.36% EarningsNov 09 BMO Avg Volume18.14K Price1.87
SMA202.08% SMA50-0.68% SMA200-15.43% Trades Volume4,732 Change-2.30%
Date Action Analyst Rating Change Price Target Change
Feb-09-18Initiated H.C. Wainwright Buy $5
Jan-08-24 09:00AM
Nov-09-23 09:05AM
Sep-19-23 09:05AM
Aug-23-23 09:05AM
Aug-10-23 09:05AM
09:05AM Loading…
Jul-11-23 09:05AM
Jun-15-23 09:20AM
May-24-23 09:05AM
May-12-23 09:05AM
May-02-23 09:05AM
Mar-30-23 09:05AM
Feb-06-23 09:10AM
Jan-25-23 09:05AM
Jan-23-23 09:05AM
Jan-04-23 09:05AM
09:05AM Loading…
Nov-10-22 09:05AM
Sep-26-22 09:00AM
Aug-08-22 09:05AM
Jul-12-22 09:00AM
May-12-22 09:05AM
Mar-29-22 09:05AM
Mar-21-22 08:05AM
Mar-17-22 04:05PM
Mar-01-22 09:31AM
Feb-24-22 04:05PM
Feb-02-22 11:28AM
Feb-01-22 09:00AM
Dec-17-21 04:30PM
Dec-15-21 08:00AM
03:01AM Loading…
Nov-17-21 03:01AM
Nov-10-21 04:15PM
Nov-09-21 09:00AM
Nov-04-21 03:01PM
Nov-02-21 02:20PM
Aug-14-21 03:57AM
Aug-10-21 09:10AM
Jul-30-21 03:00PM
Jul-27-21 10:00AM
May-11-21 04:35PM
Apr-15-21 09:15AM
Apr-12-21 05:41PM
Mar-23-21 09:05AM
Mar-04-21 09:15AM
Feb-16-21 01:30PM
Feb-11-21 12:24AM
Nov-12-20 09:00AM
Nov-09-20 01:39PM
Oct-21-20 09:00AM
Sep-30-20 08:30AM
Sep-29-20 08:30AM
Sep-22-20 08:30AM
Aug-07-20 09:00AM
Jul-08-20 08:30AM
Jun-26-20 09:00AM
May-27-20 09:00AM
May-14-20 09:00AM
Apr-29-20 10:02AM
Apr-16-20 05:25PM
Mar-26-20 09:00AM
Jan-31-20 07:20AM
Jan-30-20 08:00AM
Jan-16-20 12:05PM
Jan-06-20 08:58AM
Jan-03-20 09:55AM
Jan-02-20 08:51AM
Nov-04-19 09:15AM
Nov-01-19 09:00AM
Sep-18-19 09:30AM
Aug-19-19 09:25AM
Aug-05-19 09:00AM
Jun-07-19 10:25AM
Jun-06-19 06:42AM
May-16-19 09:10AM
May-15-19 09:00AM
Apr-15-19 09:00AM
Apr-08-19 04:29PM
Apr-03-19 09:30PM
Apr-01-19 05:33PM
Mar-14-19 09:45AM
Mar-12-19 12:22PM
Mar-08-19 01:00PM
Feb-19-19 09:00AM
Feb-12-19 09:30AM
Feb-08-19 07:00AM
Feb-07-19 09:00AM
Feb-06-19 12:15PM
Feb-05-19 12:45PM
Jan-31-19 01:24PM
Jan-30-19 09:52PM
Jan-28-19 11:27PM
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Bedford, MA.